Coronavirus Update 1120 GMT Mar 12

One test determines who lives and who dies.

Other new learning: hospitalized patients shed virus for 8-37 days so isolation is ALWAYS necessary inside the hospital

Okay, it is possible some of you will end up going to the hospital with a possible infection. A study published 72 hours ago from Wuhan teaches that, of all the diagnostic tests you can do when you show up at the hospital, and there are dozens, only ONE matters. This includes all blood tests as well as even chest x-rays.

Before diving into it I want to pause and say again, even if you end up in a hospital, like the 191 patients in this study did in Wuhan, China, in the middle of a completely swamped medical system, 72% of the patients still survived!

We’re going to make it through this folks!

Okay, preparing for the worst case scenario:

Write the words “d-dimer test” on a slip of paper and put it in your wallet or purse with your driver’s license/ID.

Why? read on:

Findings: A simple blood test called “d-dimer test” looks for blood clots. Every hospital in the world can run it. In this study, patients arriving at the hospital with a value above 1.0 microgram/mL had an ‘odds ratio’ (OR) of 18.4 of dying compared to patients below 0.5, who were defined as 1.0. Between 0.5 and 1.0 it was an increased chance of dying but not significant. This means you are over 18 times more likely to die if you fail this blood test. 93% of the folks above 1.0 at entry didn’t make it.

Age: NOT a factor. Don’t let them say ‘ you’re old so you will die more easily.’ While the average age of survivors (56 y) was younger than non-survivors (69 y) the impact of this difference was only an odds ratio of 1.1, or a 10% higher risk, compared to a 1840% increased risk for d-dimer!

Other organ problems: as expected, if you show up with this virus and problems with other organs you are worse off. Surprisingly, heart disease was the worse, OR 21.4; chronic lung disease, OR 5.4; hypertension, OR 3.1; diabetes, 2.9. So heart disease alone is worse than the d-dimer test but when the whole clinical picture is looked at heart disease drops out, leaving the d-dimer test. Detail: in this study they used something called the SOFA=Sequential Organ Failure Assessment for this part of the analysis. So tell them to calculate this as well.

Let’s thank the doctors on the front lines in Wuhan, China for putting this together to benefit the rest of the world!

The figure, which contains a clinical summary of surviving and non-surviving patients, contains the reference to the article in Lancet.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer